Drug intelligence / Profile preview

APSLXR

Development stage: Discontinued
Lead developer: Apsen Farmacêutica
Modality: Small Molecules
Administration: Oral

Overview

APSLXR is an oral small molecule drug developed by Apsen Farmaceutica for the treatment of Meniere's disease and other vertigo of vestibular origin. It was investigated in early clinical trials to evaluate its safety and pharmacokinetics in patients with these conditions. The precise mechanism of action has not been publicly disclosed, and the development program was discontinued after phase 1 trials[1][2][6][8].

Beyond the preview

Go deeper on APSLXR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APSLXR.

Explore the full profile